1.Laboratory Animal Research Center, Zhejiang Chinese Medical University, Hangzhou 310053, China;
2.Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
Abstract��
Lipoprotein- associated phospholipase A2 (Lp- PLA2) is a member of phospholipases superfamily which can hydrolyze oxidative phospholipid in low density lipoprotein (LDL), and produce two proinflammatory mediators including lysophosphatidylcholine (lysoPC) and oxidized free fatty acid. Thus, Lp- PLA2 is believed to mediate the inflammatory processes that lead to atherogenesis. Recent studies indicated that Lp- PLA2 acts as a new marker in the inflammatory process and is an independent predictor of the cardiovascular diseases. Many Lp- PLA2- targeted inhibitors have been designed to deal with the key enzyme involving in atherosclerosis. Darapladib is the specific inhibitor which is closest to the market among the rest and is drawn wide attention as an emerging therapy for atherosclerosis, and the clinical phase �� trials have been completed. Numerous experiments have confirmed that Darapladib could decrease the activity of Lp- PLA2, reduce inflammatory reaction and disrupt the development of atherosclerosis. In this paper, the authors summarized the mechanism of Lp- PLA2 and Darapladib in atherosclerosis, and the recent advances on the pharmacodynamics of Darapladib in recent years.
MA Quan-Xin-,
CHEN Min-Li-*,
WANG Yi-Ping-
.Pharmacodynamics Recent Advances of a Lipoprotein-associated Phospholipase A2 Specific Inhibitor Darapladib[J] Chinese Pharmaceutical Journal, 2015,V50(4): 317-322
��
[1]
LIBBY P, RIDKER P M, HANSSON G K. Progress and challenges in translating the biology of atherosclerosis . Nature, 2011, 473(7347): 317-325.
[2]
CHARO I F, TAUB R. Anti-inflammatory therapeutics for the treatment of atherosclerosis.Nat Rev Drug Discov, 2011, 10(5): 365-376.
[3]
IRIBARREN C, GROSS M D, DARBINIAN J A, et al. Association of lipoprotein-associated phospholipase A2 Mass and Activity With Calcified Coronary Plaque in Young Adults The CARDIA Study. Arteriosclerosis Throm Vasc Biol, 2005, 25(1): 216-221.
[4]
HERRMANN J, MANNHEIM D, WOHLERT C, et al. Expression of lipoprotein-associated phospholipase A2 in carotid artery plaques predicts long-term cardiac outcome . Eur Heart J, 2009, 30(23): 2930-2938.
[5]
SCHALOSKE R H, DENNIS E A. The phospholipase A2 superfamily and its group numbering system.BBA-Md Cell Bid L, 2006, 1761(11): 1246-1259.
[6]
STAFFORINI D M. Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Cardiovasc Drugs Ther, 2009, 23(1): 73-83.
[7]
DENNIS E A, CAO J, HSU Y H, et al. Phospholipase A2 enzymes: Physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention . Chem Rev, 2011, 111(10): 6130-6185.
[8]
RIZOS E, TAMBAKI A P, GAZI I, et al. Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome. Prostag, Leukotr Ess, 2005, 72(3): 203-209.
[9]
THEILMEIER G, DE GEEST B, VAN VELDHOVEN P P, et al. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice. Faseb J, 2000, 14(13): 2032-2039.
[10]
TURUNEN P, JALKANEN J, HEIKURA T, et al. Adenovirus-mediated gene transfer of Lp-PLA2 reduces LDL degradation and foam cell formation in vitro. J Lipid Res, 2004, 45(9): 1633-1639.
[11]
TURUNEN P, PUHAKKA H, RUTANEN J, et al. Intravascular adenovirus-mediated lipoprotein-associated phospholipase A2 gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Atherosclerosis, 2005, 179(1): 27-33.
[12]
ALI M, MADJID M. Lipoprotein-associated phospholipase A2: A cardiovascular risk predictor and a potential therapeutic target. Future Cardiol, 2009, 5(2): 159-173.
[13]
MCCONNELL J P, HOEFNER D M. Lipoprotein-associated phospholipase A2. Clin Lab Med, 2006, 26(3):679-697.
[14]
SILVA I T, MELLO A P Q, DAMASCENO N R T. Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A2 (Lp-PLA2): A review. Lipids Health Dis, 2011, 10(1): 170-179.
[15]
CASLAKE M J, PACKARD C J. Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease . Curr Opin Lipidol, 2003, 14(4): 347-352.
[16]
KHUSEYINOVA N, IMHOF A, ROTHENBACHER D, et al. Association between Lp-PLA2 and coronary artery disease: Focus on its relationship with lipoproteins and markers of inflammation and hemostasis. Atherosclerosis, 2005, 182(1): 181-188.
[17]
KOENIG W, TWARDELLA D, BRENNER H, et al. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arteriosclerosis Throm Vas Biol, 2006, 26(7): 1586-1593.
[18]
CORSON M A, JONES P H, DAVIDSON M H. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol, 2008, 101(12): 41-50.
[19]
PERSSON M, NILSSON J , NELSON J J, et al. The epidemiology of Lp-PLA2: Distribution and correlation with cardiovascular risk factors in a population-based cohort . Atherosclerosis, 2007, 190(2): 388-396.
[20]
KOLODGIE F D, BURKE A P, SKORIJA K S, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arteriosclerosis Throm Vas Biol, 2006, 26(11): 2523-2529.
[21]
DAVIDSON M H, CORSON M A, ALBERTS M J, et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol, 2008, 101(12): 51-57.
[22]
ALBERT M A, GLYNN R J, WOLFERT R L, et al. The effect of statin therapy on lipoprotein associated phospholipase A2 levels . Atherosclerosis, 2005, 182(1): 193-198.
[23]
ASCER E, BERTOLAMI M C, VENTURINELLI M L, et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients . Atherosclerosis, 2004, 177(1): 161-166.
[24]
ZHANG F J, WANG Y P. Research progress of lipoprotein-associated phospholipase A2 and its inhibitors . Foreign Med Sci (Sect Pharm)(����ҽѧ:ҩѧ�ֲ�), 2006, 33(4): 300-303.
[25]
CORSON M A. Darapladib: An emerging therapy for atherosclerosis . Ther Adv Cardiovasc Disease, 2010, 4(4): 241-248.
[26]
BLACKIE J A, BLOOMER J C, BROWN M J B, et al. The identification of clinical candidate SB-480848: A potent inhibitor of lipoprotein-associated phospholipase A2 . Bioorg Med Chem Lett, 2003, 13(6): 1067-1070.
[27]
WILENSKY R L, SHI Y I, MOHLER E R, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development . Nat Med, 2008, 14(10): 1059-1066.
[28]
WANG W, ZHANG J, WU W, et al. Inhibition of lipoprotein-associated phospholipase A2 ameliorates inflammation and decreases atherosclerotic plaque formation in ApoE-deficient mice. Plos One, 2011, 6(8): e23425.
[29]
HU M, ZHANG J, WANG W, et al. The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice . Acta Pharmacol Sin(�й�ҩ��ѧ��), 2011, 32(10): 1253-1258.
[30]
ACHARYA N K, LEVIN E C, CLIFFORD P M, et al. Diabetes and hypercholesterolemia increase blood-brain barrier permeability and brain amyloid deposition: Beneficial effects of the lpPLA2 inhibitor darapladib. J Alzheimer′s Dis, 2013, 35(1):179-198.
[31]
MOHLER E R, BALLANTYNE C M, DAVIDSON M H, et al. The effect of Darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalentthe results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol, 2008, 51(17): 1632-1641.
[32]
SERRUYS P W, GARC��A-GARC��A H M, BUSZMAN P, et al. Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque . Circulation, 2008, 118(11): 1172-1182.
[33]
GARCíA-GARC��A H M, OEMRAWSINGH R M, BRUGALETTA S, et al. Darapladib effect on circulating high sensitive troponin in patients with acute coronary syndromes. Atherosclerosis, 2012, 225(1):142-147.
[34]
WHITE H, HELD C, STEWART R, et al. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. Am Heart J, 2010, 160(4): 655-661.
[35]
WHITE H D, HELD C. STEWART R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med, 2014,370(18):1702-1711.
[36]
O′DONOGHUE M L, BRAUNWALD E, WHITE H D, et al. Study design and rationale for the stabilization of plaques using Darapladib—Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome . Am Heart J, 2011, 162(4): 613-619.
[37]
O′DONOGHUE M L, BRAUNWALD E, WHITE H D, et al.Effect of darapladib on major coronary events after an acute coronary syndrome: The SOLID-TIMI 52 randomized clinical trial. JAMA,2014,312(10):1006-1015.
[38]
KOCH M, WIESE M. Gen expression signatures of angiocidin and darapladib treatment connect to therapy options in cervical cancer. J Cancer Res Clin,2013,139(2):259-267.
[39]
MULLARD A. GSK′s darapladib failures dim hopes for anti-inflammatory heart drugs. Nat Rev Drug Discov, 2014,13(7):481-482.
2015, Vol. 50 
